<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89696">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01937390</url>
  </required_header>
  <id_info>
    <org_study_id>205.517</org_study_id>
    <nct_id>NCT01937390</nct_id>
  </id_info>
  <brief_title>Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>Post-Marketing Observational Study of the Impact of Adherence to Treatment With Once-Daily Administered Long-Acting Bronchodilators (LABAs / LAMAs) on Patients Health Related Quality of Life in COPD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the study is to observe the effect of adherence to once-daily administered
      long-acting bronchodilators (long-acting ß2-agonists [LABAs] / long-acting muscarinic
      antagonists [LAMAs]) on patients health related quality of life (HR-QoL) and to assess the
      relation between symptoms improvement and adherence to Chronic Obstructive Pulmonary Disease
      (COPD) maintenance therapy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical COPD Questionnaire (CCQ) toal score change from baseline at month 13 (Visit 4)</measure>
    <time_frame>13 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of COPD exacerbations leading to hospitalization, per patient</measure>
    <time_frame>13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first COPD exacerbation</measure>
    <time_frame>13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first COPD exacerbation leading to hospitalization</measure>
    <time_frame>13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCQ total score at month 13 (Visit 4)</measure>
    <time_frame>13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of COPD exacerbations, per patient</measure>
    <time_frame>13 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1300</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>LAMA/LABA Patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium Bromide 2.5 µg</intervention_name>
    <description>Respimat® inhaler and cartridge Solution for inhalation</description>
    <arm_group_label>LAMA/LABA Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indacterol 300 µg</intervention_name>
    <description>inhalation powder</description>
    <arm_group_label>LAMA/LABA Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium Bromide 18 µg</intervention_name>
    <description>HandiHaler® device Inhalation powder, hard capsule</description>
    <arm_group_label>LAMA/LABA Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indacterol 150 µg</intervention_name>
    <description>inhalation powder</description>
    <arm_group_label>LAMA/LABA Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Caucasians
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Male or female, above 40 years of age

          2. Patients clinically diagnosed of COPD with no history suggestive of asthma:

               1. by scores &gt;=5 in the COPD Population Screener,

               2. by a clinical diagnosis of COPD made by pulmonologists or internists,

               3. by a Forced Expiratory Volume (FEV1)/ Forced Vital Capacity (FVC6) ratio of
                  &lt;=0.70 and a FEV1 &lt;=80% of the predicted value as assessed by copd-6
                  (Vitalograph, UK);

          3. Maintenance treatment-naïve COPD patients who have been prescribed once daily
             long-acting bronchodilators (LABAs / LAMAs) for the first time at enrolment into the
             study

          4. Patients who are able to provide signed informed consent

          5. Patients who agree to be contacted for telephone/ SMS reminders via call center

        Exclusion criteria:

          1. Patients with contraindications to the prescribed medication

          2. Patients with any disorder that would prevent the patient from being able to complete
             questionnaires either verbally or by self-completion

          3. Pregnant or lactating women or women of childbearing potential not using an
             acceptable method of contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Upper Egypt</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dammam</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jeddah</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dubai</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
    <country>Lebanon</country>
    <country>Saudi Arabia</country>
    <country>United Arab Emirates</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 3, 2017</lastchanged_date>
  <firstreceived_date>September 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
